Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).

Basit Öğe Kaydı
dc.contributor.authorAbulkhair, O.
dc.contributor.authorUslu, R.
dc.contributor.authorSezgin, C.
dc.contributor.authorBueyuekberber, S.
dc.contributor.authorDarwish, T.
dc.contributor.authorIsikdogan, A.
dc.contributor.authorGumus, M.
dc.contributor.authorDane, F.
dc.contributor.authorSevinc, A.
dc.contributor.authorHalawani, H.
dc.contributor.authorUncu, D.
dc.contributor.authorMarrero, N.
dc.contributor.authorTobler, J.
dc.contributor.authorSoares, C.
dc.contributor.authorLandis, S.
dc.contributor.authorMoraes, E.
dc.contributor.authorGidekel, R.
dc.contributor.authorSantillana, S.
dc.contributor.authorNunez, P.
dc.contributor.authorCagnolati, S.
dc.contributor.authorRodriguez, J. G.
dc.date.accessioned2019-10-27T21:55:47Z
dc.date.available2019-10-27T21:55:47Z
dc.date.issued2012
dc.departmentEge Üniversitesien_US
dc.identifier.doi10.1158/0008-5472.SABCS12-OT1-1-08
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.urihttps://doi.org/10.1158/0008-5472.SABCS12-OT1-1-08
dc.identifier.urihttps://hdl.handle.net/11454/48272
dc.identifier.volume72en_US
dc.identifier.wosWOS:000209704900083en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Assoc Cancer Researchen_US
dc.relation.ispartofCancer Researchen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleClinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu